ACIU (AC Immune) Moat Score: 4/10 (As of Jul. 01, 2026)


ACIU AC Immune SA ACIU
25 GF Score
Price $2.38
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Moat Score?

AC Immune ACIU -10.53% 25 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates ACIU with a GF Score™ of 25/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,400 Biotechnology companies, AC Immune ranks better than 88.79% on this metric.

AC Immune has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

AC Immune has Narrow Moat: AC Immune SA has a discernible but modest moat due to its valuable intellectual property and patents in the biotech sector. However, it lacks strong market leadership, brand strength, and customer switching costs to elevate it to a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AC Immune might have Narrow Moat - Discernible but modest moat.

AC Immune  (NAS:ACIU) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AC Immune Moat Score Related Terms

ACIU vs NAUT, IVVD, OTLK: Moat Score Comparison

For the Biotechnology subindustry, AC Immune's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AC Immune Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Moat Score distribution charts can be found below:

* The bar in red indicates where AC Immune's Moat Score falls into.


ACIU
25GF Score
AC Immune SA ACIU
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
AC Immune (ACIU) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AC Immune ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is AC Immune's Moat Score too high?
AC Immune's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. AC Immune's value of 4 is 100% above this industry median. Based on the distribution chart, AC Immune ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AC Immune has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Moat Score compare to NAUT and IVVD?
According to the Biotechnology industry distribution chart, AC Immune ranks #157 out of 1400 companies for Moat Score. This places AC Immune in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. AC Immune's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AC Immune's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AC Immune's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.38 — trading 217.3% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. AC Immune's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AC Immune (ACIU), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.38 is trading 217.3% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Moat Score: 4
  • GF Value™: $0.75 vs. price of $2.38 (217.3% above fair value)
  • GF Score™: 25/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1400)

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
25GF Score

Get the complete analysis for ACIU

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price
$0.75
GF Value